Cambridge, UK-based digital health startup PocDoc has raised £5 million in Pre-A funding to support its growth and expand its innovative diagnostic testing platform.
MMC Ventures, Molten VC, Simplyhealth Ventures, and KHP Ventures led the investment round.
Making Diagnostics Accessible
PocDoc focuses on improving access to diagnostic testing for cardiovascular, metabolic, and renal diseases. The company’s technology revolves around an app-based platform that integrates:
- Microfluidic Assay (MFA) technology, enabling precise and complex diagnostic testing.
- Cloud-based AI diagnostics, ensuring fast, accurate assessments.
With this combination, PocDoc provides an end-to-end solution for diagnosing and managing major diseases, including enabling patients to access follow-up care, treatment, and clinical consultations—all through a smartphone or tablet.
Key Features of the PocDoc Platform
- The MFA platform performs complex multi-marker tests with clinical-grade accuracy.
- PocDocOS® offers the infrastructure for point-of-care testing, including machine learning integration, real-time alerts, and workflow management.
- PocDoc’s tests are accessible via pharmacies, NHS-supported regions, online retailers, and their own website.
Use of Funds
PocDoc plans to use the newly raised funds to fuel its rapid growth, particularly through:
- Strengthening partnerships with pharmacies, retailers, and corporate clients.
- Expanding NHS collaborations across the UK.
- Enhancing its platform capabilities to improve diagnostic access and care delivery.
Driving the Future of Healthcare
Founded by Steve Roest, Dr. Vladimir Gubala, and Dr. Kiran Roest, PocDoc is addressing a critical need in healthcare: providing scalable, accessible tools for disease prevention and management. With the newly raised funds, PocDoc intends to further its mission of making diagnostic testing a seamless, accessible, and effective part of everyday healthcare.